The clinical benefit response in treatment of unresectable pancreatic carcinoma by endoscopic ultrasongraphy-guided interstitial implantation of iodine-125 seeds combined with gemcitabine chemotherapy
- VernacularTitle:125I粒子植入联合吉西他滨化疗治疗胰腺癌临床受益疗效评价
- Author:
Yueping JIANG
;
Zhendong JIN
;
Zhaoshen LI
;
Yiqi DU
;
Yan LIU
;
Jie CHEN
;
Xianbao ZHAN
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Endoscopic Ultrasonography;
Brachytherapy;
Iodine-125;
Gemcitabine
- From:
Chinese Journal of Pancreatology
2008;8(5):289-291
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical benefit response (CBR) in treating the unresectable pancreatic carcinoma by applying the EUS guided iodine-125 seed implantation combined with chemotherapy of gemeitabine and comparing chemotherapy of gemcitabine alone. Methods Forty-one patients with unresectable pancreatic carcinoma were randomly divided into two groups, one group (Group A) included 21 cases which underwent EUS-guided iodine-125 seed implantation combined with gemcitabine chemotherapy, the rest 20 cases (Group B) were treated with gemcitabine chemotherapy alone. EUS-guided iodine-125 seed implantation were carried according to the treatment plan system (TPS), following chemotherapy after 1 week. Gemcitabine was administered at the dose of 1 000 mg/m2, through intravenous administration once a week for 3 consecutive weeks every 4 weeks. CBR was assessed. Results CBR of Group A was 57.1% and median time to CBR was 1 week and median duration of CBR was 21 weeks, while CBR of Group B was 25%, and median time to CBR was 4 weeks and median duration of CBR was 15 weeks (P<0.01). Conclusions EUS-guided iodine-125 seed implantation combined with chemotherapy of gemcitabine was superior to gemcitabine chemotherapy alone in the term of CBR in patients with unresectable pancreatic carcinoma.
